References
- Osório C, Jones N, Jones E, Robbins I, Wessely S, Greenberg N. Combat experiences and their relationship to post-traumatic stress disorder symptom clusters in UK military personnel deployed to Afghanistan. Behav Med. 2017. doi:10.1080/08964289.2017.1288606
- Nevin RL. Mefloquine and posttraumatic stress disorder. In: Ritchie EC, ed. Textbook of military medicine. Forensic and ethical issues in military behavioral health. Washington, DC: Borden Institute; 2015:277–96.
- Nevin RL, Leoutsakos JM. Identification of a syndrome class of neuropsychiatric adverse reactions to mefloquine from latent class modeling of FDA adverse event reporting system data. Drugs R D. 2017;17:199–210.
- Nevin RL, Byrd AM. Neuropsychiatric adverse reactions to mefloquine: a systematic comparison of prescribing and patient safety guidance in the US, UK, Ireland, Australia, New Zealand, and Canada. Neurol Ther. 2016;5:69–83.
- Livezey J, Oliver T, Cantilena L. Prolonged neuropsychiatric symptoms in a military service member exposed to mefloquine. Drug Saf—Case Reports. 2016;3:7.
- Nevin RL. Screening for symptomatic mefloquine exposure among veterans with chronic psychiatric symptoms. Fed Pract. 2017;34:12–14.
- Eick-Cost AA, Hu Z, Rohrbeck P, Clark LL. Neuropsychiatric outcomes after mefloquine exposure among US military service members. Am J Trop Med Hyg. 2017;96:159–66.
- Croft AM, Darbyshire AH, Jackson CJ, van Thiel PP. Malaria prevention measures in coalition troops in Afghanistan. JAMA. 2007;297:2197–200.
- UK Ministry of Defence. Mefloquine hydrochloride prescribing in the UK Armed Forces: 1 April 2007 to 31 March 2015. 2016. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/491134/20160112_Adhoc_Statistical_Bulletin_Mefloquine_prescribing_in_the_UK_Armed_Forces_-O.pdf
- UK House of Commons Defence Committee. An acceptable risk ? The use of lariam for military personnel. Fourth Report of Session 2015–16, HC567. 2016. Available at: http://www.publications.parliament.uk/pa/cm201516/cmselect/cmdfence/567/567.pdf
- Terrell AG, Forde ME, Firth R, Ross DA. Response: Malaria chemoprophylaxis and self-reported impact on ability to work. J Travel Med. 2016;23:tav029.
- Alegana VA, Wright JA, Nahzat SM, et al. Modelling the incidence of Plasmodium vivax and Plasmodium falciparum malaria in Afghanistan 2006–2009. PLoS One. 2014;9:e102304.